Status:
COMPLETED
Maintenance Therapy in Acute Myeloid Leukemia (AML) Patients
Lead Sponsor:
University Health Network, Toronto
Collaborating Sponsors:
Celgene Corporation
Conditions:
Acute Myeloid Leukemia
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine if Revlimid will help maintain patients with acute myeloid leukemia in remission.
Detailed Description
At present, the majority of AML patients \>60 years of age that achieve CR and thereafter successfully complete further chemotherapy, are not candidates for allogeneic bone marrow transplantation (all...
Eligibility Criteria
Inclusion
- Diagnosis of Acute myeloid leukemia in remission.
- Able to take aspirin 81mgs daily.
Exclusion
- Pregnant or breast feeding females.
- Known hypersensitivity to thalidomide.
- Any prior use of lenalidomide.
Key Trial Info
Start Date :
June 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2015
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT00957385
Start Date
June 1 2008
End Date
April 1 2015
Last Update
June 19 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Health Network, Princess Margaret Hospital
Toronto, Ontario, Canada, M5G 2M9